ISM001-055 is a potentially first-in-class small molecule targeting TNIK developed utilizing generative AI. The history of discovery, design and development including target discovery, ...

Today, Insilico Medicine announced encouraging results from their phase 2a trial (NCT05938920) on the use of ISM001-055 for treating patients with idiopathic pulmonary fibrosis (IPF). These ...

The Type 055 is the Chinese navy's newest class of destroyer. Due to its long-range firepower, it has been described as "the world's most potent warship." There are currently six of these ships in ...

INS018_055 is set to enter a global, randomized multi-site Phase II trial “early” this year. “Study endpoints include safety, tolerability, pharmacokinetics, and efficacy to include change ...

ISM001-055’s Phase IIa study(NCT05938920) was a randomized, double-blind, placebo-controlled trial that enrolled 71 patients with IPF across 21 sites in China.

INS018_055 is Insilico’s first wholly owned program in which AI was used to identify a novel target and generate novel small molecules through the company’s Pharma.AI platform.

Three Type 055 destroyers of the Chinese People’s Liberation Army (PLA) Navy have been recently conducting separate training exercises in the Yellow Sea, South Pacific, and South China Sea.